Phase I-II Study of Avastin [bevacizumab] + Bortezomib for Patients With Recurrent or Refractory Non-Squamous NSCLC [non-small cell lung cancer].

Trial Profile

Phase I-II Study of Avastin [bevacizumab] + Bortezomib for Patients With Recurrent or Refractory Non-Squamous NSCLC [non-small cell lung cancer].

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Bortezomib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jan 2012 Planned end date (May 2007) added as reported by ClinicalTrials.gov.
    • 20 Jan 2012 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 05 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top